A Phase I study of Adriamycin administered i.p. was per formed in 10 ovarian cancer patients who were refractory to systemic chemotherapy. Adriamycin was infused in 2 liters of Inpersol via a semipermanent Tenckhoff dialysis catheter. Adriamycin was administered for a 4-hr dwell every 2 weeks with concentrations ranging from 9 to 54 Â¡UM. The dose-limiting toxicity of i.p. Adriamycin was a sterile peritonitis. Severe abdominal pain with ascites and adhesions was observed at concentrations greater than 36 fiM. There were three objective responses, and two other patients had a marked reduction in ascites formation while on treatment. The objective responses were in patients who had small volume (<2-cm masses) dis ease. The clinical activity of i.p. Adriamycin was probably the result of cytotoxicity and not merely a sclerotic effect, since the reduction in ascites was accompanied by a decrease in the number of malignant cells and by a corresponding inability of these cells to form tumor colonies in soft agar.
INTRODUCTION
The determining factor for the successful treatment of ovar ian cancer is the eradication of all intraabdominal disease. The majority of patients with ovarian cancer have Stage III disease at the time of diagnosis (2) , and postoperative therapy is directed towards the elimination of any residual disease in the pelvis, mesentery, under the diaphragms, or in the paraaortic ' To whom requests for reprints should be addressed at National Cancer Institute, Building 10. Room 12N226, 9000 Rockville Pike, Bethesda. Md. 20205. Received January 26, 1982; accepted June 7. 1982. lymph nodes. Combination chemotherapy regimens have pro duced clinical complete responses in 35 to 48% of patients with advanced disease (1, 5, (17) (18) (19) . However, surgical restaging has demonstrated that pathological complete remis sions occur in only 20 to 25% of the patients treated with combination chemotherapy (19) . Patients with residual disease following an initial response to chemotherapy are usually re fractory to the continued administration of systemic chemo therapy. Furthermore, even those patients with a surgically documented complete response to systemic chemotherapy remain at risk for recurrent i.p. disease (18, 19) . The Division of Cancer Treatment, National Cancer Institute, has been evaluating i.p. chemotherapy as a therapeutic mo dality in intraabdominal cancers. In contrast to earlier trials of i.p. chemotherapy in which antineoplastic agents were admin istered i.p. in a small volume, the current trials at the National Cancer Institute have utilized a semipermanent Tenckhoff cath eter, which has allowed repeated i.p. administration of chemotherapeutic agents in a large volume. Pharmacological mod eling studies had suggested that such an approach would be advantageous in diseases confined to the abdominal cavity (3) . Phase I trials in ovarian and colon cancer patients of i.p. methotrexate (9) and 5-fluorouracil (15) have demonstrated that repeated dialysis via a Tenckhoff catheter produces a pharmacological advantage (peak i.p. drug level/peak plasma level) of 36 and 298, respectively.
Adriamycin is an antineoplastic agent that has several fea tures which make it a potentially advantageous drug for Â¡.p. administration in ovarian cancer patients, (a) It is an active agent in ovarian cancer with a 40% response rate in previously untreated patients (4, 20) . (b) Its molecular weight and hydrophilic properties suggest a slow peritoneal clearance (10); (c) the i.p. route is curative in 70% of mice with a transplantable murine ovarian cancer, which has a metastatic pattern similar to human ovarian cancer (11, 12) . Adriamycin i.v. had no effect on survival. And (d) a dose-response relationship between Adriamycin and in vitro cytotoxicity to human ovarian cancer cells has been demonstrated with a clonogenic assay (13, 14) . Ovarian cancer cells obtained from patients who had progres sive disease after treatment with a non-Adriamycin-containing chemotherapy regimen demonstrated in vitro resistance to concentrations of Adriamycin achievable by i.v. administration of Adriamycin. Significant in vitro cytotoxicity was, however, observed following exposure of the same cells to a concentra tion of Adriamycin which, while not achievable by i.v. therapy, could potentially be attained by Â¡.p. administration.
This report describes the clinical and pharmacological re sults of a Phase I trial of i.p. Adriamycin in 10 patients with advanced ovarian cancer. In addition, the clinical results are compared to the in vitro cytotoxicity of Adriamycin as measured
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in thÃ¨clonogenic assay with ovarian cancer cells from patients receiving i.p. Adriamycin.
MATERIALS AND METHODS
Patient Characteristics. Ten patients with histologically confirmed ovarian adenocarcinoma were treated with i.p. Adriamycin. All the patients had failed a primary systemic chemotherapy regimen: L-phenylalanine mustard, one patient; hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil (18), 2 patients; or cyclophosphamide, hexamethylmelamine, c/s-platinum, 5-fluorouracil (19), 7 pa tients. In addition, 9 of 10 patients had been treated with i.p. 5-fluorouracil (15) . Four patients had tumor masses less than 2 cm in diameter prior to the administration of i.p. Adriamycin and 6 patients had bulky intraabdominal disease.
Tenckhoff Catheter. Semipermanent Tenckhoff silastic dialysis catheters were implanted surgically into the peritoneal cavity under local anesthesia. The catheter was implanted through a s.c. tunnel and secured with a Dacron felt cuff. The patients were instructed in catheter care as described previously (9, 10, 15, 16) .
Dialysis Schedule. Patients were treated with Adriamycin (Adria Laboratories, Columbus, Ohio) in 2 liter of Inpersol (Abbott Laborato ries, North Chicago, III.) containing 1.5% dextrose. Heparin was not added to the bottles containing Inpersol because of precipitation with Adriamycin. All dialysis bottles were warmed to 37Â°prior to instillation.
Adriamycin levels were measured in the Inpersol dialysate, and only a single peak was detected with high-pressure liquid chromatography (see below).
The patients received a single 4-hr instillation of Adriamycin contain ing dialysate every 2 weeks unless otherwise indicated. The dialysis procedure consisted of 3 separate exchanges. The first 2-liter bottle containing only Inpersol was instilled and immediately drained. The second 2-liter bottle contained Adriamycin and was allowed to dwell for 4 hr and was then drained. The third 2-liter bottle was plain Inpersol and was immediately drained after instillation. The Adriamycin concentration of the dialysate was progressively increased with each dialysis course until toxicity became prohibitive. The initial 3 patients were treated at 9 /IM Adriamycin (10 mg/2 liters) followed by 3 patients who were started at 18 UM (20 mg/2 liter), 3 patients at 36 /JM (40 mg/2 liters), and one patient whose initial dialysate was 54 Â¡Ã•M (50 mg/2 liters).
In Vitro Sensitivity of Adriamycin. The in vitro sensitivity to Adria mycin was determined with the soft-agar cloning assay as described previously for ovarian cancer cells (7, 13) . This assay was described initially by Hamburger et al. (6, 7) . Human ovarian cancer cells were obtained from either malignant ascites or malignant washings collected via the Tenckhoff catheter and exposed for 1 hr to various concentra tions of Adriamycin. The effect on tumor colony-forming cells was then compared to untreated controls. In 2 patients, the colony-forming ability of cells collected immediately prior to and immediately after an in vivo exDOSure to a 4-hr dwell with Adriamvcin was compared. Determination of Adriamycin Levels. Plasma from 5 ml of blood collected in EDTA glass tubes and peritoneal fluid (withdrawn through the Tenckhoff catheter) was frozen at -20Â°until analysis. The samples were prepared for analysis by adding 50 ng daunomycin as an internal standard and 1.0 ml of 0.1 M sodium borate buffer, pH 9.8, to 1.0 ml of the plasma or peritoneal fluid. Each sample was then extracted with 17 ml of chloroform:methanol (4:1, v/v) , and the organic layer was transferred to a conical tube and evaporated to dryness under nitrogen at room temperature. The residue was dissolved in 100 n\ methanol and injected into the high-pressure liquid Chromatograph. Standards containing 0 to 200 ng/ml of Adriamycin were processed in an identical fashion as the samples of blood or peritoneal fluid.
Drug levels were measured on a high-pressure liquid Chromato graphie system with fluorescent detection using a phenyl reversephase column (8) . Quantitation of drug concentrations was achieved by measuring the peak height ratios of drug internal standards of the samples and comparing them to a standard curve constructed by plotting peak height ratio versus concentration of the known standards using a least-squares plot.
RESULTS
Tenckhoff Catheter. Ten patients with advanced refractory ovarian cancer were treated with a total of 38 courses of i.p. Adriamycin (range, one to 6 cycles/patient).
Tenckhoff cath eters were well tolerated by the patients. Two of the patients experienced mild abdominal pain, which was positional and probably due to irritation from the catheter tip. There were no instances of bacterial peritonitis during i.p. Adriamycin therapy.
Toxicity. The i.p. administration of Adriamycin in ovarian cancer patients was associated with gastrointestinal toxicity, myelosuppression, and peritoneal irritation ( Table 1 ). The lim- Â¡tingtoxicity of i.p. Adriamycin was a dose-dependent perito nitis (Table 2) . At a concentration of 9 /IM (10 mg/2 liter) with a 4-hr dwell, only 1 of 3 cycles produced mild abdominal discomfort lasting less than 24 hr (1 + peritoneal toxicity). In contrast, at a concentration of 54 /tM (60 mg/2 liters), 2 of 6 courses were associated with pain lasting from 1 to 3 days requiring mild analgesics (2+ toxicity), and 4 of 6 courses at this dose resulted in persistent abdominal pain lasting 3 to 10 days requiring codeine analgesia (3+ peritoneal toxicity). The development of 2+ and 3+ peritoneal toxicity led us to in crease the interval between dialysis from 2 to 3 weeks at the higher concentrations of Adriamycin (>36 /Â¿M). The higher doses of i.p. Adriamycin also resulted in the formation of sterile ascites in 2 patients, which persisted for 1 and 3 months. There were no instances of drug-induced intestinal obstruction, al though 2 patients also had an increase in asymptomatic ab dominal adhesions after i.p. Adriamycin, noted at a secondlook laparotomy and a restaging peritoneoscopy. All 3 patients who had 3+ peritoneal irritation at 54 fiM had decreased abdominal pain when the concentration was decreased to 36 JUM.
The peritoneal toxicity did not appear to increase with an increased number of cycles of i.p. Adriamycin. Nine patients received more than one cycle of dialysis with 4 patients receiv ing either 5 or 6 cycles of i.p. Adriamycin. The peritoneal toxicity was correlated with the highest concentration of i.p. Adriamycin. As noted above, as the concentration of a subse quent cycle was decreased in these patients, the severity of the peritoneal toxicity also decreased. The recommended start ing dose with acceptable peritoneal toxicity in a Phase II study of i.p. Adriamycin would be 27 to 36 fiM administered in 2 liters with a 4-hr dwell every 2 to 3 weeks for a total of 6 cycles.
Less frequent and less severe toxicities included nausea and vomiting and myelosuppression. Only one patient had nausea and vomiting lasting longer than 24 hr. However, this patient also had a tumor-related partial small bowel obstruction. Three patients had myelosuppression with WBC nadirs of 3.6/cu mm, 2.7/cu mm, and 1.4/cu mm, which developed after a concentration of 36 fiM. One patient also developed thrombocytopenia of 17,000/cu mm, which was a preterminal event developing 21 days after a dose of 36 /IM (40 mg/2 liters).
Pharmacological Studies. The mean 4-hr i.p. Adriamycin level was 15% of the instilled drug concentration. The mean disappearance half-life (sum of absorption and binding to i.p. tissues) of Adriamycin from the peritoneal dialysate was 1.6 hr. The plasma levels of Adriamycin peaked within 30 min of i.p. administration and then gradually declined over 24 h (Chart 1). The plasma levels following an i.p. dose of 60 mg/2 liters (54 /IM) are compared to the plasma levels observed in 2 different patients who received the same dose i.v. The peak plasma level following the i.v. bolus was 10 times greater than the peak plasma levels observed after i.p. administration. Except for the difference in the peak plasma levels, the pharmacokinetics of Adriamycin clearance from the blood was similar for the first 24 hr after Â¡.p. and i.v. administration, although the absence of Adriamycin levels 24 to 72 hr after i.p. administration did not allow for an exact comparison of i.p. versus i.v. area under the curve values. Adriamycin metabolites were detected in the plasma after i.p. administration of 36 to 54 /IM Adriamycin.
The i.p. administration of Adriamycin produced a marked pharmacological advantage with the mean peak peritoneal fluid level being 474 times greater than the mean peak plasma level after an i.p. dose of 40 mg/2 liters (36 /IM) ( Table 3) . The mean peritoneal level at the completion of the 4-hr dwell was 166 times greater than the corresponding plasma level. Similar ratios of peritoneal fluid Adriamycin levels to plasma levels were observed after an i.p. dose of 60 mg/2 liters (54 /Ã•M) ( Table 3) .
Response Data. There were 3 responses in the 10 patients with refractory ovarian cancer who received i.p. Adriamycin. One patient had a negative peritoneoscopy after 6 cycles of i.p. Adriamycin [peak dose, 60 mg/2 liters (54 /ÃOEM)]. She was not treated for 18 months until a subsequent peritoneoscopy revealed malignant cells in the peritoneal washings. Another patient had multiple small peritoneal tumor nodules prior to i.p. Adriamycin. At the completion of 6 cycles of i.p. Adriamycin [maximum dose, 50 mg/2 liters (45 /JM)], a single focus of malignant cells was found in the omentum. A third patient whose only evidence for ovarian cancer was cytologically malignant peritoneal washings developed negative washings which persisted for 4 months. Two other patients had marked reduction in ascites production while receiving i.p. Adriamycin. Instead of 3 to 5 liters of ascites production per week requiring frequent paracentesis, both patients did not require therapeutic paracentesis after the initial cycle of i.p. Adriamycin. In addi tion, the number of cells in the ascites decreased from 50 to 100 x 106 cells/liter to 5 to 10 X 106 cells/liter. Both of these patients, however, developed progressive disease outside the peritoneum.
In vitro cytotoxicity to Adriamycin was evaluated using the human tumor stem cell assay (Table 4) . Ovarian cancer colony formation was observed in 8 of 10 specimens; however, only 4 specimens (40%) had sufficient colony formation to evaluate in vitro cytotoxicity. Of these 4 specimens, 3 demonstrated sensitivity to Adriamycin (>70% colony reduction) following a 1-hr exposure to Adriamycin at 10 /Â¿g/ml(18 /JM). Two of the specimens were obtained from patients who had a marked reduction in ascites production while on i.p. Adriamycin. Tumor cells from both patients collected immediately after a 4-hr exposure to 10 /Â¿g/ml(18 /Â¿M) failed to form colonies in soft agar. The in vitro cytotoxicity data in this small series of patients is consistent with the dose-response relationships for Adria mycin in ovarian cancer cells reported previously (14) . All the cells that were collected from the peritoneum immediately following an in vivo exposure to Adriamycin demonstrated intranuclear Adriamycin-specific fluorescence.
DISCUSSION
The results of this trial have demonstrated that i.p. Adria mycin can be administered safely to refractory ovarian cancer patients. The rationale for this trial was based on pharmacolog ical modeling studies (3) and experimental studies in murine ovarian cancer (11, 12) and with human ovarian cancer cells in a short-term soft-agar culture (13, 14) . The pharmacokinetic basis for i.p. therapy is the slower absorption (clearance) of many drugs from the peritoneum compared to the rate of Table 4 In vitro sensitivity to Adriamycin elimination from the rest of the body. Consequently, tumors confined to the abdomen will be exposed to a higher concen tration of cytotoxic drugs than systemic levels. The administra tion of drugs in a large volume (2 liters of dialysate) through a semipermanent Tenckhoff catheter helps ensure uniform dis tribution of drug throughout the peritoneal cavity and allows for repeated drug administration to maintain a constant high level of i.p. drug. In theory, the greatest antitumor effect would be achieved with an i.p.-administered drug, which resulted in cytotoxic levels i.p. as well as in the systemic circulation.
The experimental rationale for i.p. Adriamycin in ovarian cancer patients was based on studies in murine ovarian cancer and with human ovarian cancer cells. In the murine model, it was demonstrated that i.p. Adriamycin was more beneficial than i.v. Adriamycin because of higher intracellular Adriamycin levels with a resultant increased suppression of DNA synthesis (11) in tumor cells. In vitro dose-response studies in human ovarian cancer cells, either from malignant effusions or cyto logically malignant peritoneal washings, demonstrated 3 sep-arate patterns of Adriamycin sensitivity using colony survival in soft agar (13, 14) . The greatest degree of sensitivity was observed in cells from previously untreated patients whereas cells from patients who had relapsed after therapy with sys temic Adriamycin demonstrated marked in vitro resistance. Even after a 1-hr exposure to 18 /IM Adriamycin, a concentra tion 10 times greater than the peak level after i.v. administra tion, the mean inhibition of colony formation was only 20%. In contrast, cells obtained from patients who had relapsed after therapy with a non-Adriamycin combination had a dose-de pendent survival of colony formation. After exposure to Adria mycin at the peak levels achievable by i.v. administration, there was no significant inhibition of colony formation, but at a 18 /Â¿M exposure, the mean percentage of colony inhibition was 90%. These results suggest that if the Adriamycin concentra tion to which human ovarian cancer cells are exposed could be increased to 10-fold the peak plasma level achievable after i.v. therapy, then clinical benefit may be obtained for that group of patients who became refractory to non-Adriamycin combi nations. Patients who have relapsed after therapy with systemic Adriamycin are not likely to benefit from such an approach, since Adriamycin resistance in these cells was of such a magnitude in the in vitro studies that significant cytotoxicity was not achieved even by increasing the drug levels to 10 times that achievable by i.v. administration.
The Phase I trial of i.p. Adriamycin demonstrated that the levels of Adriamycin which were required to produce significant in vitro cytotoxicity (in cells from previously untreated patients or after treatment with a non-Adriamycin regimen) could in fact be achieved by administration of Adriamycin via the Tenckhoff catheter. The pharmacological advantage (peak i.p. level/peak plasma level) achieved with Adriamycin was 474. This was greater than that observed with either methotrexate, 36 (7), or 5-fluorouracil, 298 (8) .
In this small series of patients, the clinical activity of i.p. Adriamycin (3 partial responses) was confined to patients who had a small volume of disease at the initiation of i.p. Adriamycin. These results are in agreement wrth the experimental obser vation that Adriamycin does not penetrate deeply into intraab dominal tumor masses. Using the intrinsic fluorescence of Adriamycin, we have demonstrated previously that Adriamycin does not penetrate more than 6 to 8 cell layers into intraab dominal murine ovarian tumors (12) .
The major and dose-limiting toxicity of i.p. Adriamycin was peritonitis. Abdominal pain became apparent in all patients with a dose of 18 fiM or greater. At higher doses of i.p. Adriamycin, the severity and intensity of the abdominal pain increased. In addition, sterile ascites and peritoneal adhesions also resulted after treatment at doses greater than 36 JUM.Since 9 of 10 patients in this trial had been treated previously with i.p. 5-fluorouracil, which also can result in peritoneal irritation (8) , the peritoneal toxicity of i.p. Adriamycin may have been a result of, in part, an already drug-damaged peritoneum. The clinical activity of i.p. Adriamycin was probably a cytotoxic effect and not due to peritoneal sclerosis because (a) the decrease in volume of ascites following i.p. Adriamycin was associated with a net decrease in concentration of malignant cells in the ascites and (b) ovarian cancer cells obtained from patients immediately following i.p. Adriamycin had a marked decrease in colony formation compared to cells obtained prior to the instillation of i.p. Adriamycin.
On the basis of this Phase I trial of i.p. Adriamycin, we have initiated a Phase II trial of i.p. Adriamycin in refractory ovarian cancer patients who have not received systemic Adriamycin and who have residual masses less than 2 cm in diameter.
